论文部分内容阅读
目的:观察氨溴索与溴已新在治疗慢性阻塞性肺疾病急性发作的疗效。方法:2012年1月~2013年11月,我院共收治120例确诊的慢性阻塞性肺疾病急性发作的患者,随机分为2组,治疗组和对照组各60名。两组患者均在联合抗炎、抗病毒、持续低流量吸氧、支气管扩张剂应用及机械通气等治疗基础上,对照组给予溴已新4-8mg静脉滴注bid治疗,治疗组给予氨溴索30-60mg静脉滴注bid治疗,7-10天后,观察并比较2组患者的症状和临床指标。结果:治疗组临床有效率为90%;对照组临床有效率为70%;具有显著性差异(P<0.05);2组患者肺功能变化存在显著性差异(P<0.01);2组患者在喘憋时间,咳嗽的剧烈程度及痰堵发生率方面,具有显著性差异(P<0.05)。结论:在常规治疗基础上,加入氨溴索,能有效改善患者的临床症状,并显著提高患者的肺功能,具有一定的临床价值,可在临床中推广使用。
Objective: To observe the efficacy of ambroxol and bromhexine in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods: From January 2012 to November 2013, 120 cases of acute exacerbation of chronic obstructive pulmonary disease (COPD) admitted to our hospital were randomly divided into two groups, 60 in each of the treatment group and the control group. The two groups of patients were combined with anti-inflammatory, anti-virus, continuous low-flow oxygen, bronchodilators and mechanical ventilation based on the treatment group was given bromine new 4-8mg intravenous bid treatment, the treatment group given AMB Cable 30-60mg intravenous bid treatment, 7-10 days after the observation and comparison of two groups of patients with symptoms and clinical indicators. Results: The clinical effective rate was 90% in the treatment group and 70% in the control group, with significant difference (P <0.05). There was significant difference in the pulmonary function between the two groups (P <0.01) Wheezing time, the severity of cough and the incidence of phlegm blocking, there was a significant difference (P <0.05). CONCLUSION: Ambroxol can effectively improve the clinical symptoms and improve the lung function of patients with routine therapy. It has certain clinical value and can be widely used in clinical practice.